Submit Manuscript  

Article Details


Efficacy and Toxicity of Addition of Bevacizumab to Chemotherapy in Patients with Metastatic Colorectal Cancer

Author(s):

Wen-Cong Ruan, Yue-Ping Che, Li Ding and Hai-Feng Li*   Pages 1 - 7 ( 7 )

Abstract:


Background: Pre-treated patients with first-line treatment can be offered a second treatment with the aim of improving their poor clinicalprognosis. The therapy of metastatic colorectal cancer (CRC) patients who did not respond to first-line therapy has limited treatment options. Recently, many studies have paid much attention on the efficacy of bevacizumab as adjuvant treatment for metastatic colorectal cancer.

Objectives: We aim to evaluate the efficacy and toxicity of bevacizumab plus chemotherapy compared with bevacizumab-naive based chemotherapy as second-line treatment in people with metastatic CRC.

Methods: Electronic databases were searched for eligible literatures updated to March 2018. Randomized-controlled trials comparing addition of bevacizumab to chemotherapy without bevacizumab in MCRC patients were included, of which the main interested results were the efficacy and safety profiles of addition of bevacizumab in patients with MCRC as second-line therapy.

Result: Five trials were eligible in the meta-analysis. Patients who received the combined bevacizumab and chemotherapy treatment in MCRC as second-line therapy showed a longer overall survival (OS) (OR=0.80,95%CI=0.72-0.89, P<0.0001) and progression-free survival (PFS) (OR=0.69,95%CI=0.61-0.77, P<0.00001). In addition, there was no significant difference in objective response rate (ORR) (RR=1.36,95%CI=0.82-2.24, P=0.23) or sever adverse event (SAE) (RR=1.02,95%CI=0.88-1.19, P=0.78) between bevacizumab-based chemotherapy and bevacizumab-naive based chemotherapy.

Conclusion: Our results suggest that the addition of bevacizumab to the chemotherapy therapy could be an efficient and safe treatment option for patients with metastatic colorectal cancer as second-line therapy and without increase the risk of adverse event.

Keywords:

Bevacizumab, metastatic colorectal cancer (mCRC), second-line treatment, overall survival (OS), progression-free survival (PFS), meta-analysis.

Affiliation:

Department of Rehabilitation, The Children’s Hospital, Zhejiang University School of Medicine, Hangzhou 310000, Department of Rehabilitation, The Children’s Hospital, Zhejiang University School of Medicine, Hangzhou 310000, Department of Rehabilitation, The Children’s Hospital, Zhejiang University School of Medicine, Hangzhou 310000, Department of Rehabilitation, The Children’s Hospital, Zhejiang University School of Medicine, Hangzhou 310000



Read Full-Text article